by Rosalyn Carson-DeWitt, MD
Dementia is a general loss of mental abilities. It can include a loss of ability to think, reason, learn, and understand. To be considered dementia, these mental losses must be severe enough to interfere with day-to-day activities. Dementia must also have:
Causes of dementia include:
Risk Factors TOP
Risk factors for dementia include:
Symptoms often begin mildly. They often get more severe over time. Symptoms vary according to the cause of the dementia, but often include:
Your doctor may diagnose dementia through:
There are no blood tests or exams that can diagnose Alzheimer's disease. Certain types of brain imaging such as a SPECT or a PET scan may aid in a diagnosis. Tests to rule out other causes of dementia and other medical conditions that may mimic dementia include:
The doctor will also check to see if you have depression. It can often present like dementia.
Currently, there are no treatments to cure many types of dementia. Some medication may help to decrease the symptoms of dementia or slow its course.
Two types of medicines that may be used to reduce the symptoms of Alzheimer's disease include:
Treatments that are being studied include:
This type of support is critical for people with dementia. Behavioral and environmental support includes:
People with dementia often develop psychiatric symptoms. You may need appropriate treatment, such as:
While the exact cause of dementia is not known, these steps may help to reduce your risk:
Alzheimers Association of Canada
Toronto Dementia Network
Alzheimer's disease. EBSCO DynaMed website. Available at: https://dynamed.ebscohost.com/about/about-us. Updated July 11, 2012. Accessed August 22, 2012.
Alzheimer's disease medications fact sheet. National Institute on Aging website. Available at: http://www.nia.nih.gov/Alzheimers/Publications/medicationsfs.htm. Updated July 2010. Accessed August 22, 2012.
Alzheimer's disease and non-Alzheimer’s dementia. EBSCO Natural and Alternative Treatments website. Available at: http://www.ebscohost.com/healthLibrary. Updated July 7, 2012. Accessed August 22, 2012.
Beers MH, Berkow R, Bogin RM, et al. The Merck Manual of Geriatrics. 3rd ed. Whitehouse Station, NJ: Merck & Co. Inc.; 1995-2000.
Cecil RL, Goldman L, Bennett JC. Cecil Textbook of Medicine. 21st ed. Philadelphia, PA: WB Saunders Company; 2000.
DeKosky S, Jeff D, Williamson A, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial JAMA. 2008;300:2253-2262.
Dementia evaluation. EBSCO DynaMed website. Available at: https://dynamed.ebscohost.com/about/about-us. Updated July 19, 2012. Accessed August 22, 2012.
American Academy of Neurology website. Available at: http://www.aan.com/professionals. Accessed August 22, 2012.
Gidoni R, et al. Cerebrospinal fluid biomarkers for Alzheimer’s disease: the present and the future. Neurodegen Dis. 2011;8:413-20.
Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. BMJ. 2005;331:321-327.
Ledger AJ & Baker FA. An investigation of long-term effects of group music therapy on agitation levels of people with Alzheimer’s Disease. Aging & Mental Health. 2007;11: 330-338.
Mendez MF, Cummings JL. Dementia: A clinical Approach. 3rd ed. Boston, MA: Butterworth Heinemann; 2003.
Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol. 2009;66(10):1210-1215.
Obrien JT, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy Bodies. Arch Neurol. 2004; 61: 919-925.
Schneider L, Dagerman K, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.
Tierney L. Current Medical Diagnosis & Treatment. 44th ed. New York, NY: McGraw-Hill; 2005.
12/16/2008 DynaMed's Systematic Literature Surveillance https://dynamed.ebscohost.com/about/about-us: Farquhar C, Marjoribanks J, Lethaby A, Suckling J, Lamberts Q. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2008;CD004143.
2/24/2009 DynaMed's Systematic Literature Surveillance https://dynamed.ebscohost.com/about/about-us: Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;CD003120.
9/18/2009 DynaMed's Systematic Literature Surveillance https://dynamed.ebscohost.com/about/about-us: Anstey KJ, Mack HA, Cherbuin N. Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. Am J Geriatr Psychiatry. 2009;17:542-555.
1/8/2010 DynaMed's Systematic Literature Surveillance https://dynamed.ebscohost.com/about/about-us: Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA. 2009;302:2663-2670.
Last reviewed September 2012 by Rimas Lukas, MD
Last Updated: 09/27/2012